Download PDF
Thromb Haemost 1999; 82(03): 1008-1010
DOI: 10.1055/s-0037-1614319
Letters to the Editor
Schattauer GmbH

Outpatient Use of Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity

K. J. Savage
1   From the University of Western Ontario, Ottawa, Ontario, Canada
,
P. S. Wells
3   Ontario and the University of Ottawa, Ottawa, Ontario, Canada
,
V. Schulz
1   From the University of Western Ontario, Ottawa, Ontario, Canada
,
D. Goudie
3   Ontario and the University of Ottawa, Ottawa, Ontario, Canada
,
B. Morrow
1   From the University of Western Ontario, Ottawa, Ontario, Canada
,
M. Cruickshank
1   From the University of Western Ontario, Ottawa, Ontario, Canada
2   London Health Sciences Centre, London, Canada
,
M. J. Kovacs
1   From the University of Western Ontario, Ottawa, Ontario, Canada
2   London Health Sciences Centre, London, Canada
› Author Affiliations
Further Information

Publication History

Received 23 November 1998

Accepted after resubmission 06 May 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

Upper extremity deep vein thrombosis (DVT) is now recognized as a major cause of morbidity and mortality. There is little information regarding the most effective treatment of this condition. We report a prospective cohort study of the use of low molecular weight heparin (LMWH) in the outpatient management of upper extremity DVT. Forty-six patients were managed as outpatients for objectively documented upper extremity DVT with dalteparin (200 aXa u/kg), for a minimum of five days. Warfarin was usually initiated on the first day with a target INR of 2.0-3.0. Most patients had an underlying malignancy or a history of a central line. All patients were followed for 12 weeks from diagnosis. Only one patient had a major bleed. No patients developed pulmonary emboli. One patient had a recurrence of DVT during the treatment with LMWH with extension of the existing thrombus. Seven patients died, all due to their underlying disease. This study supports the safety and effectiveness of dalteparin in the treatment of upper extremity DVT. Given that these patients were treated as outpatients, there is a potential for huge cost savings.

 

  • References

  • 1 Horattas MC, Wright DJ, Fenton AH, Evans DM, Oddi MA, Kamienski RW, Shields EF. Changing concepts of deep venous thrombosis of the upper extremity – report of a series and review of the literature. Surgery 1988; 104: 561-7.
    PubMedGoogle Scholar
  • 2 Donayre CE, White GH, Mehringer SM, Wilson SE. Pathogenesis determines late morbidity of axillosubclavian vein thrombosis. Am J Surg 1986; 152: 179-84.
    CrossrefPubMedGoogle Scholar
  • 3 Harley DP, White RA, Nelson RJ, Mehringer CM. Pulmonary embolism secondary to venous thrombosis of the arm. Am J Surg 1984; 147: 221-4.
    CrossrefPubMedGoogle Scholar
  • 4 Aburahma AF, Sadler DL, Robinson PA. Axillary-subclavian vein thrombosis. Changing patterns of etiology diagnostic and therapeutic modalities. Am Surg 1991; 57: 101-7.
    PubMedGoogle Scholar
  • 5 Becker DM, Philbrick JT, Walker FB. Axillary and subclavian vein thrombosis: Prognosis and treatment. Arch Intern Med 1991; 151: 1934-43.
    CrossrefPubMedGoogle Scholar
  • 6 Monreal M, Lafoz E, Ruiz J, Valls R, Alastrue A. Upper extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 1991; 99: 280-3.
    CrossrefPubMedGoogle Scholar
  • 7 Hill S, Berry RH. Subclavian vein thrombosis: A continuing challenge. Surgery 1990; 108: 1-9.
    PubMedGoogle Scholar
  • 8 Hung SS. Deep vein thrombosis of the arm associated with malignancy. Cancer 1989; 64: 531-5.
    CrossrefPubMedGoogle Scholar
  • 9 Prandoni P, Polistena P, Bernardi E, Cogo A, Casara D, Verlato F, Angelini F, Simioni P, Signorini GP, Benedetti L, Girolami A. Upper extremity deep vein thrombosis. Risk factors, diagnosis and complications. Arch Intern Med 1997; 157: 57-62.
    CrossrefPubMedGoogle Scholar
  • 10 Hull RD, Rosckob G, Pineo GF. Subcutaneous LMWH compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. New Engl J Med 1992; 326: 975-88.
    CrossrefPubMedGoogle Scholar
  • 11 Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, deHaes H, van den Belt AGM, Sagnard L, d’Azemar P, Büller HR. for the Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. New Engl J Med 1996; 334: 682-7.
    CrossrefPubMedGoogle Scholar
  • 12 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New Engl J Med 1996; 334: 677-81.
    CrossrefPubMedGoogle Scholar
  • 13 Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74: 360-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins: A meta-analysis. Arch Intern Med 1995; 155: 601-7.
    CrossrefPubMedGoogle Scholar
  • 15 Prandoni P, Lensing AWA, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, Cate JWT. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441-5.
    CrossrefPubMedGoogle Scholar
  • 16 Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. New Engl J Med 1997; 337: 663-9.
    CrossrefPubMedGoogle Scholar
  • 17 The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. New Engl J Med 1997; 337: 657-62.
    CrossrefPubMedGoogle Scholar
  • 18 Wells PS, Kovacs MJ, Forgie MA, Bormanis J, Goudie D, Morrow B, Kovacs J. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin: A comparison of patient self-injection to home care injection. Arch Intern Med 1998; 158: 1809-12.
    CrossrefPubMedGoogle Scholar
  • 19 Rodger M, Bredeson C, Wells PS, Beck J, Kearns B, Huebsch LB. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. Can Med Assoc J 1998; 159: 931-8.
    PubMedGoogle Scholar
  • 20 Kovacs MJ, Cruickshank M, Wells PS, Kim H, Chin-Yee I, Morrow B, Boyle E, Kovacs J. Randomized assessment of a warfarin nomogram for initial oral anticoagulation after venous thromboembolic disease. Haemostasis 1998; 28: 62-9.
    PubMedGoogle Scholar
  • 21 Koot HWJ, Veen HF. Local thrombolytic therapy for axillary subclavian vein thrombosis. Neth J Surg 1991; 43: 71-4.
    PubMedGoogle Scholar
  • 22 Roos DB. Axillary-subclavian vein occlusion. Vascular Surgery. ed. WB Saunders; Philadelphia: 1984: 1385-93.
    Google Scholar
  • 23 Swinton NW, Edgett JW, Hall RJ. Primary subclavian – axillary vein thrombosis. Circulation 1968; 38: 737-45.
    CrossrefPubMedGoogle Scholar
  • 24 Ameli FM, Minas T, Weiss M, Provan JL. Consequences of “conservative conventional management of axillary vein thrombosis”. Canadian Journal of Surgery 1987; 30: 167-9.
    PubMedGoogle Scholar
  • 25 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
    PubMedGoogle Scholar